The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: The relationship between the outcome and the clinicopathological characteristics

Nagao, Tomoya; Kinoshita, Takayuki; Hojo, Takashi; Tsuda, Hitoshi; Takagi, Kenji; Fujiwara, Yasuhiro

doi:10.1016/j.breast.2011.12.011

Cited by 98 publications

(83 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[12][13][14] Nineteen of the 20 MPBC cases (95%) in this series harbored 36 alterations that could potentially lead to a targeted, therapeutic treatment option (mean [SD], 1.8 [1.06] per tumor). This result is similar to a series 41 of 273 routine (non-MPBC) breast cancers evaluated using the same assay, where 246 (90%) harbored at least one potentially actionable alteration.…”

Section: Resultsmentioning

confidence: 99%

“…8,9 These findings combined with messenger RNA (mRNA) profiling studies indicate that most MPBCs are so-called triple-negative breast cancers (TNBCs) that cluster with the basaloidphenotype cancers in the breast cancer molecular-portraits system. [10][11][12] However, although the TNBC and basaloid types of breast cancer are classically associated with responsiveness to cytotoxic chemotherapy, 13,14 metastatic MPBC is generally regarded as a chemoresistant, highly aggressive form of the disease. 15,16 Given the poor prognosis and reduced response to treatment for MPBC, this study was performed to evaluate potential, targeted treatment opportunities for patients with MPBC.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Genomic Profiling of Advanced-Stage, Metaplastic Breast Carcinoma by Next-Generation Sequencing Reveals Frequent, Targetable Genomic Abnormalities and Potential New Treatment Options

Ross

Badve

Wang

et al. 2015

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.-Metastatic metaplastic breast carcinoma (MPBC) is an uncommon, but aggressive, tumor resistant to conventional chemotherapy.Objective.-To learn whether next-generation sequencing could identify potential targets of therapy for patients with relapsed and metastatic MPBC.Design.-Hybridization capture of 3769 exons from 236 cancer-related genes and 47 introns of 19 genes commonly rearranged in cancer was applied to a minimum of 50 ng of DNA extracted from 20 MPBC formalin-fixed, paraffinembedded specimens and sequenced to high uniform coverage.Results.-The 20 patients with MPBC had a median age of 62 years (range, 42-86 years). There were 9 squamous (45%), 9 chondroid (45%), and 2 spindle cell (10%) MPBCs, all of which were high grade. Ninety-three genomic alterations were identified, (range, 1-11) with 19 of the 20 cases (95%) harboring an alteration that could potentially lead to a targeted treatment option. The mostcommon alterations were in TP53 (n ¼ 69; 75%), PIK3CA (n ¼ 37; 40%), MYC (n ¼ 28; 30%), MLL2 (n ¼ 28; 30%), PTEN (n ¼ 23; 25%), CDKN2A/B (n ¼ 19; 20%), CCND3 (n ¼ 14; 15%), CCNE1 (n ¼ 9; 10%), EGFR (n ¼ 9; 10%), and KDM6A (n ¼ 9; 10%); AKT3, CCND1, CCND2, CDK4, FBXW7, FGFR1, HRAS, NF1, PIK3R1, and SRC were each altered in a single case. All 16 MPBCs (100%) that were negative for ERBB2 (HER2) overexpression by immunohistochemistry and/or ERBB2 (HER2) amplification by fluorescence in situ hybridization were also uniformly (100%) negative for ERBB2 amplification by next-generation sequencing-based copy-number assessment.Conclusions.-Our results indicate that genomic profiling using next-generation sequencing can identify clinically meaningful alterations that have the potential to guide targeted treatment decisions in most patients with metastatic MPBC.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Genomic Profiling of Advanced-Stage, Metaplastic Breast Carcinoma by Next-Generation Sequencing Reveals Frequent, Targetable Genomic Abnormalities and Potential New Treatment Options

Ross

Badve

Wang

et al. 2015

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…Nagao et al 14 in their study have indicated a poor response to chemotherapy in patients with apocrine carcinomas, although HER-2/neu enriched carcinomas tend to have the highest rate of complete response to neoadjuvant chemotherapy. However, according to Tsutsumi 5 there appears to be a potential unique response to androgen (fluoxymesterone) administration as a part of treatment which is under investigation.…”

Section: Discussionmentioning

confidence: 96%

Apocrine Carcinoma of Breast- A Rare Case Report

Uday¹,

N²

2017

jemds

View full text Add to dashboard Cite

“…Some studies have indicated that clinical outcomes in ILC are similar to those described in invasive ductal carcinoma (IDC) [2,3], while others have demonstrated worse clinical outcomes [4,5]. Hormone therapy (HT) use is related to an increased risk of invasive breast cancer, most strongly associated with ILC [6,7].…”

Section: Introductionmentioning

confidence: 97%

Invasive lobular carcinoma stable for 4.5 years in a postmenopausal woman user of hormone therapy for 25 years

Conde¹,

Sousa²,

Sousa³

et al. 2013

Gynecological Endocrinology

View full text Add to dashboard Cite

We present a case of a 72-year-old woman referred to the breast disorder service due to abnormalities on mammography and breast ultrasound. The patient reported using different hormone therapy (HT) formulations during 25 years and had stopped taking HT for 4 years. Physical examination showed no alterations in the breasts or axilla. Mammography from 2012 detected asymmetry at the 3 o'clock position in the anterior right breast. Ultrasound revealed an irregular, hypoechoic mass with indistinct margins, and posterior acoustic shadowing. A retrospective analysis of mammographies from 2007, 2009 and 2010 showed that a very subtle asymmetry had existed since 2007. Follow-up imaging demonstrated no change in asymmetry during 4.5 years. The patient underwent breast-conserving therapy and sentinel lymph node biopsy. Histopathologic examination demonstrated classic invasive lobular carcinoma. There were no sentinel node metastases. The patient received radiotherapy and endrocrine therapy. This case demonstrates that breast cancer may remain stable and not grow for many years. This aspect should be kept in mind by all professionals dealing with women's healthcare, in particular HT users who may develop breast cancer with a less aggressive behavior. Any suspicious finding on mammography, despite being unchanged for a number of years, must be investigated. Gynecol EndocrinolDownloaded from informahealthcare.com by The University of Manchester on 11/02/14 For personal use only. 304 D. M. Conde et al. Gynecol Endocrinol, 2013; 29(4): 301-304 Gynecol Endocrinol Downloaded from informahealthcare.com by The University of Manchester on 11/02/14 For personal use only.

show abstract

The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: The relationship between the outcome and the clinicopathological characteristics

Abstract: The response to standardized NAC and prognosis varies for each histological type. For some types, the prognosis was not associated with the clinicopathological response to NAC. Innovative regimens should therefore be investigated for each histological type to achieve the best response.

Cited by 98 publications

References 41 publications

Genomic Profiling of Advanced-Stage, Metaplastic Breast Carcinoma by Next-Generation Sequencing Reveals Frequent, Targetable Genomic Abnormalities and Potential New Treatment Options

Genomic Profiling of Advanced-Stage, Metaplastic Breast Carcinoma by Next-Generation Sequencing Reveals Frequent, Targetable Genomic Abnormalities and Potential New Treatment Options

Apocrine Carcinoma of Breast- A Rare Case Report

Invasive lobular carcinoma stable for 4.5 years in a postmenopausal woman user of hormone therapy for 25 years

Contact Info

Product

Resources

About